Recurrence of Synovial Sarcoma

  • Research type

    Research Study

  • Full title

    Recurrence of synovial sarcoma: risk factors for relapse in a U.K. population

  • IRAS ID

    260719

  • Contact name

    Bill Robertson-Smith

  • Contact email

    bill.robertson-smith@ngh.nhs.uk

  • Duration of Study in the UK

    2 years, 9 months, 0 days

  • Research summary

    Soft tissue sarcomas are a rare group of malignant tumours of the connective tissue. Synovial sarcoma (SS) is a rare subtype of a soft tissue sarcoma, usually diagnosed as a localized disease, with the peak incidence being in the 30- 40 year age group, more often than not, presenting in the extremities as a painless mass which is increasing in size and deep within the underlying tissues.

    The National Institute of Health and Clinical Excellence (NICE) has recommended that all soft tissue sarcomas should be managed and treated as one disease therefore there is no specific treatment recommended in the case of synovial sarcoma. There has been little research into this specific disease regarding relevant treatments or which patients are most at risk of relapse.

    The primary aim of this research is to investigate factors which are associated with the likelihood of relapse in individual patients diagnosed with non-metastatic synovial sarcoma. The secondary aim of this research is to pilot a predictive model of outcome, specific to synovial sarcoma which will be internally but not externally validated to identify patients at increased risk.

    This will be an observational study using retrospective data from the East Midlands Sarcoma Service of participants aged 13 years and over with non-metastatic limb and trunk wall Synovial Sarcoma.

    Retrospective data will be collected, under an honorary contract, from Queens Medical Centre Nottingham and the University Hospitals of Leicester where the data from the East Midlands Sarcoma Service is held.

    The preliminary predictive model will enable clinicians to identify patients at risk of relapse. This will ultimately enable increased surveillance for this group so that medical intervention for disease recurrence can be timely and more effective

  • REC name

    East Midlands - Leicester South Research Ethics Committee

  • REC reference

    19/EM/0272

  • Date of REC Opinion

    1 Nov 2019

  • REC opinion

    Further Information Favourable Opinion